Alacrity Medical Innovations (AMI) seeks to transform the treatment of life-interrupting bleeding, initially for patients on anticoagulant medications (“blood thinners”) and ultimately for a broader population. We are developing novel, convenient devices for anti-coagulated patients to stop life-interrupting bleeding events at home. Alacrity Medical Innovations’ (AMI) first product is a patent-pending, novel, easy-to-use drug delivery device in combination with a unique indication for an anti-fibrinolytic (“blood clot stabilizer”). Our device will simultaneously absorb blood while delivering the anti-fibrinolytic directly to wounds to stop life-interrupting bleeding in anti-coagulated patients.
8-12 million patients estimated to be on anticoagulants (ACs).
2.8 million AC treatment visits in Q4 '14 (+38% vs Q2 '09).
Annualizes to >11 million visits in 2015.
Barnes G et al. National Trends in Ambulatory Oral Anticoagulant Use. Am J Med. 2015 December ; 128(12): 1300–1305.e2.
Available by health-care provider prescription
A topical formulation of well established anti-fibrinolytic drug.
Hand-held device to apply direct pressure and administer the medication.
Stops bleeding in a clinical or home setting saving time and the potential need for an Emergency Room or Urgent Care visit.